Drugs / AUTO CAR T cell therapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03628612 | Aug 2018 → Jul 2043 expected | T-cell non-Hodgkin lymphoma, acute lymphoblastic leukemia, diffuse large B-cell lymphoma, plasma cell myeloma | Autolus Limited | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AUTO CAR T cell therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03628612 ↗ |
| Modality | Cell therapy | “AUTO CAR T cell therapy” NCT03628612 ↗ |